OBJECTIVES: To measure disease-modifying agent adherence and persistence among patients with multiple sclerosis (MS). DESIGN: Retrospective cohort study. SETTING: Multispecialty, salaried group practice in southeast Michigan, between June 1, 2004, and June 30, 2006. PATIENTS: 224 insured adult patients with relapsing remitting MS with an outpatient visit. MAIN OUTCOME MEASURES: Medical record-documented receipt of medication recommendation and prescription. Pharmacy claims data-derived measures of dispensing and among patients with two or more dispensings, medication possession ratios (MPRs), and proportion of gap days were estimated. Among those initiating agent use, persistence was estimated. RESULTS: Mean cohort age was 47.6 years, while 77% of participants were women and 39% were black. Of patients, 81.8% had a recommendation for a disease-modifying agent, 75.0% had a prescription, and 66.5% had two or more dispensings. Among those with two or more dispensings, mean MPR between the first and last dispensing date was 83.8% (95% CI 80.8-86.8), while mean MPR for the entire 24-month period was 68.0% (64.4-71.7). MPR for the 24-month period decreased with increasing drug copayments and was lower among black patients, while MPR between the first and last dispensing date increased with increasing age. Among those initiating therapy, 43% were nonpersistent with medications within 14 months. CONCLUSION: Medication adherence and persistence among patients with relapsing remitting MS is far from monolithic. Measuring medication adherence and persistence among defined populations is useful for understanding the relationship between medication use and outcomes in practice and for targeting patients and programs to improve medication adherence.
OBJECTIVES: To measure disease-modifying agent adherence and persistence among patients with multiple sclerosis (MS). DESIGN: Retrospective cohort study. SETTING: Multispecialty, salaried group practice in southeast Michigan, between June 1, 2004, and June 30, 2006. PATIENTS: 224 insured adult patients with relapsing remitting MS with an outpatient visit. MAIN OUTCOME MEASURES: Medical record-documented receipt of medication recommendation and prescription. Pharmacy claims data-derived measures of dispensing and among patients with two or more dispensings, medication possession ratios (MPRs), and proportion of gap days were estimated. Among those initiating agent use, persistence was estimated. RESULTS: Mean cohort age was 47.6 years, while 77% of participants were women and 39% were black. Of patients, 81.8% had a recommendation for a disease-modifying agent, 75.0% had a prescription, and 66.5% had two or more dispensings. Among those with two or more dispensings, mean MPR between the first and last dispensing date was 83.8% (95% CI 80.8-86.8), while mean MPR for the entire 24-month period was 68.0% (64.4-71.7). MPR for the 24-month period decreased with increasing drug copayments and was lower among black patients, while MPR between the first and last dispensing date increased with increasing age. Among those initiating therapy, 43% were nonpersistent with medications within 14 months. CONCLUSION: Medication adherence and persistence among patients with relapsing remitting MS is far from monolithic. Measuring medication adherence and persistence among defined populations is useful for understanding the relationship between medication use and outcomes in practice and for targeting patients and programs to improve medication adherence.
Authors: Natalia Gonzalez Caldito; Shiv Saidha; Elias S Sotirchos; Blake E Dewey; Norah J Cowley; Jeffrey Glaister; Kathryn C Fitzgerald; Omar Al-Louzi; James Nguyen; Alissa Rothman; Esther Ogbuokiri; Nicholas Fioravante; Sydney Feldman; Ohemaa Kwakyi; Hunter Risher; Dorlan Kimbrough; Teresa C Frohman; Elliot Frohman; Laura Balcer; Ciprian Crainiceanu; Peter C M Van Zijl; Ellen M Mowry; Daniel S Reich; Jiwon Oh; Dzung L Pham; Jerry Prince; Peter A Calabresi Journal: Brain Date: 2018-11-01 Impact factor: 13.501
Authors: Dorlan J Kimbrough; Elias S Sotirchos; James A Wilson; Omar Al-Louzi; Amy Conger; Darrel Conger; Teresa C Frohman; Shiv Saidha; Ari J Green; Elliot M Frohman; Laura J Balcer; Peter A Calabresi Journal: Ann Neurol Date: 2015-01-13 Impact factor: 10.422
Authors: Bernard Uitdehaag; Cris Constantinescu; Peter Cornelisse; Douglas Jeffery; Ludwig Kappos; David Li; Magnhild Sandberg-Wollheim; Anthony Traboulsee; Elisabetta Verdun; Victor Rivera Journal: Ther Adv Neurol Disord Date: 2011-01 Impact factor: 6.570
Authors: Bruce A Cohen; Ben W Thrower; Carolyn A Berry; Stephanie A Stowell; William A Mencia; Rachel B Karcher Journal: Neurol Clin Pract Date: 2013-06
Authors: Peter J Jongen; Gerald Hengstman; Raymond Hupperts; Hans Schrijver; Job Gilhuis; Joseph H Vliegen; Erwin Hoogervorst; Marc van Huizen; Eric van Munster; Johnny Samijn; Els de Schryver; Theodora Siepman; Martijn Tonk; Eveline Zandbergen; Jacques ten Holter; Ruud van der Kruijk; George Borm Journal: BMC Neurol Date: 2011-03-30 Impact factor: 2.474
Authors: Kerstin Hansen; Katrin Schüssel; Marita Kieble; Johanna Werning; Martin Schulz; Robert Friis; Dieter Pöhlau; Norbert Schmitz; Joachim Kugler Journal: PLoS One Date: 2015-07-27 Impact factor: 3.240